765IGF-MTX (IGF Oncology)

765IGF-MTX is a novel biologic drug conjugate developed by IGF Oncology, LLC for the treatment of advanced myeloid malignancies, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and oligoblastic acute myeloid leukemia (O-AML). The agent consists of a variant of human insulin-like growth factor-1 (765IGF, which is similar to long-R3-IGF-1) covalently coupled to the antifolate chemotherapeutic drug methotrexate (MTX). It is designed to selectively target cancer cells that overexpress the insulin-like growth factor type 1 receptor (IGF-1R), which is common in MDS and other myeloid disorders. By binding to IGF-1R, the conjugate is internalized, delivering the cytotoxic methotrexate payload directly into the malignant cells to inhibit DNA synthesis while potentially minimizing systemic toxicity associated with conventional chemotherapy.

Other names

IGF-Methotrexate conjugateIGF/MTX